PHVS: Deucrictibant's strong efficacy and safety data support its launch as a leading oral HAE therapy
Deucrictibant demonstrated high efficacy and a favorable safety profile in severe HAE patients, positioning it as a differentiated oral therapy for both on-demand and prophylactic use. Launch preparations are advanced, with strong patient interest and a robust pipeline supporting future growth.Base…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.